| Applications: | Immunodepletion/Immunocompetition |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description : | SARS CoV-2 Spike Glycoprotein Blocking Peptide for STJ506290 is synthetically produced from the 1-100 sequence and is suitable for use in western blot applications. |
| Formulation: | Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction: | Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Immunogen Region: | 1-100 |
| Specificity: | This blocking peptide is recommended for use in combination with SARS CoV-2 Spike Glycoprotein antibody, STJ506290 |